PDCD1 and non-small cell lung carcinoma: For example, in the KEYNOTE-024 trial, the PD-1 inhibitor pembrolizumab was found to significantly improve OS compared to chemotherapy in patients with PD-L1 positive NSCLC, with a hazard ratio (HR) of 0.60 [27].